Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Rash Due to Epidermal Growth Factor Receptor Inhibitors Clinical Trial

Official title:

A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02239731
• Other study ID #: FDX104-1
• Status: Completed
• Phase: Phase 2
• First received: September 10, 2014
• Last updated: February 25, 2018
• Start date: October 2014
• Est. completion date: October 2015

Study information

• Verified date: February 2016
• Source: Foamix Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of FDX104 Antibiotic Foam in the prevention of EGFRI skin toxicity in cancer patients receiving Cetuximab or Panitumumab.

Description:

This is a phase II multicenter, randomized, double blind, vehicle controlled clinical study to evaluate the safety, tolerability and efficacy of Doxycycline Foam 4% for the prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects with Cancer Receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis.

The study consists of a screening visit, a treatment period where patients will be treated topically on the face twice daily for 5 weeks. A post-treatment follow up visit (4 weeks after end of treatment), will be performed only for subjects who have experienced unresolved possibly-related or related adverse events at the end of the treatment. Seven days after randomization and study drug initiation, subjects will start their EGFRI treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years and older

2. Subjects with any cancer receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis.

3. Scheduled to start Cetuximab or Panitumumab treatment;

4. Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or with a negative subunit hCG pregnancy test immediately prior to study entry.

5. Able to understand and provide signed informed consent.

6. Ability to reliably apply topical FDX104 and vehicle twice a day to the appropriate part of the face

7. Willingness to minimize sun exposure for 5 weeks from randomization

8. ECOG performance status 0-2.

Exclusion Criteria:

1. Prior allergic reaction or severe intolerance to Doxcycycline and/or other tetracyclines.

2. Prior allergic reaction or severe intolerance to soy or coconut oil

3. Cutaneous metastases on the face or might spread to the face.

4. The presence of any active skin disease (e.g., eczema), tattoos or other problems at application site, (i.e., located on the face) that, in the investigator's opinion, could confound the evaluation of the rash or make topical application unacceptable

5. Hair on the face (e.g beard) which would interfere with the application of the study drug or its evaluation.

6. ANC <1,500/mm3 (or<1.5x109/L), or Platelet count < 100,000/mm3 (or <100x109/L)

7. Abnormal renal functions: Serum creatinine >1.6 mg/dL or 142umol/L (SI units) or calculated estimated creatinine clearance <40 ml/min1.73 m2 based on Cockcroft and Gault formula.

8. Abnormal hepatic functions: Serum Aspartate transaminase (AST) or alanine tansaminase (ALT) >5 institutional upper limit of normal (ULN). Or Total billirubin > 2 x institutional ULN or >5 x institutional ULN if documented liver metastasis.

9. Any clinically significant safety laboratory results that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study

10. Any clinically significant finding on the physical examination that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study

11. Systemic lupus erythematosus

12. Undergoing any current biological treatment for cancer other than the prescribed EGFRI

13. Treatment with topical antibiotics, anti-acne medication and other topical treatments on the face within 14 days prior to treatment start. Use of topical corticosteroids within 2 weeks prior to baseline; only mild to moderate topical steroids are allowed outside the head and neck area. The area should not exceed 10% of the whole body surface area. In body folds, such as axillary and inguinal regions, only mild topical steroids are allowed in short term use (=15 consecutive days).

14. Treatment with systemic antibiotics 7 days prior to treatment start.

15. Known or suspected pregnancy, or lactation or planned pregnancy (females)

16. Previous enrolment in a clinical trial involving investigational drug or a medical device within 30 days before provision of written informed consent for the study

17. Subjects who are mentally or physically unable to comply with all aspects of the study.

Related Conditions & MeSH terms

• Rash Due to Epidermal Growth Factor Receptor Inhibitors

Intervention

Drug:
• FDX104 (4% Doxycycline)
FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks

Locations

Country	Name	City	State
Israel	Soroka Medical Center	Be'er-Sheva
Israel	Rambam Medical Center	Haifa
Israel	Hadassah Medical Center	Jerusalem
Israel	Rabin Medical Center	Petah-Tikva
Israel	Assaf Harofeh medical center	Rishon LeZion
Israel	Sourasky medical center	Tel Aviv
Israel	Sheba medical center	Tel Hashomer

Sponsors (1)

Lead Sponsor	Collaborator
Foamix Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Reduction of skin toxicity by FDX104 in cancer patients treated with EGFRI	Reduction in numbers of papulo-pustular eruptions in the treatment side compared to the placebo treated side and reduction in erythema or edema areas in the treatment side compared to the placebo treated side estimated by the MESTT grading scale developed by the Multinational Association of Supportive Care in Cancer (MASCC) and by visual scale of rash severity (Scope A. scale)	9 weeks
Primary	To investigate the safety and tolerability of FDX104 in cancer patients receiving EGFRI	To demonstrate the safety and tolerability of FDX104 in terms of skin tolerability, adverse events, serious adverse events and vital signs in subjects with advanced cancer treated by EGFRI.	9 weeks